CA2313805A1 - Method for reducing susceptibility to hiv infection - Google Patents

Method for reducing susceptibility to hiv infection Download PDF

Info

Publication number
CA2313805A1
CA2313805A1 CA002313805A CA2313805A CA2313805A1 CA 2313805 A1 CA2313805 A1 CA 2313805A1 CA 002313805 A CA002313805 A CA 002313805A CA 2313805 A CA2313805 A CA 2313805A CA 2313805 A1 CA2313805 A1 CA 2313805A1
Authority
CA
Canada
Prior art keywords
cells
cd40l
cell
hiv
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002313805A
Other languages
English (en)
French (fr)
Inventor
Elaine K. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2313805A1 publication Critical patent/CA2313805A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002313805A 1997-12-19 1998-12-18 Method for reducing susceptibility to hiv infection Abandoned CA2313805A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6835597P 1997-12-19 1997-12-19
US60/068,355 1997-12-19
US9847498P 1998-08-31 1998-08-31
US60/098,474 1998-08-31
PCT/US1998/027005 WO1999032138A1 (en) 1997-12-19 1998-12-18 Method for reducing susceptibility to hiv infection

Publications (1)

Publication Number Publication Date
CA2313805A1 true CA2313805A1 (en) 1999-07-01

Family

ID=26748884

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002313805A Abandoned CA2313805A1 (en) 1997-12-19 1998-12-18 Method for reducing susceptibility to hiv infection

Country Status (6)

Country Link
EP (1) EP1059932A1 (de)
JP (1) JP2001526241A (de)
AU (1) AU2004199A (de)
CA (1) CA2313805A1 (de)
IL (1) IL136731A0 (de)
WO (1) WO1999032138A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
AU2002232447A1 (en) * 2000-11-02 2002-05-15 Immunex Corporation Method of enhancing lymphocyte-mediated immune responses
US7175838B2 (en) 2001-08-23 2007-02-13 The United States Of America Represented By The Department Of Health And Human Services Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
AU2006202318A1 (en) 2005-06-02 2006-12-21 Wing-Yee Chan The preparation of multipotent stem cells and the use thereof
CN101522210B (zh) 2006-09-18 2017-03-22 阿肯色大学评议会 增强免疫应答的组合物和方法
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PL2214701T3 (pl) 2007-11-01 2017-01-31 The Board Of Trustees Of The University Of Arkansas Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria
UA110024C2 (uk) 2010-01-21 2015-11-10 Вакцинний вектор і спосіб посилення імунної відповіді
KR102007132B1 (ko) 2010-06-09 2019-08-05 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
NZ711019A (en) 2013-02-14 2019-07-26 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
EP2968423A4 (de) 2013-03-15 2016-11-09 Univ Arkansas Zusammensetzungen und verfahren zur verstärkung der immunreaktionen gegen enterale pathogene
BR112018072592A2 (pt) 2016-05-03 2019-04-16 The Board Of Trustees Of The University Of Arkansas vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
ATE267607T1 (de) * 1993-12-23 2004-06-15 Immunex Corp Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
JP3657271B2 (ja) * 1995-03-01 2005-06-08 イミュネックス・コーポレーション 病原性または日和見感染性生物に感染した哺乳動物の治療のための組成物

Also Published As

Publication number Publication date
WO1999032138A1 (en) 1999-07-01
AU2004199A (en) 1999-07-12
EP1059932A1 (de) 2000-12-20
IL136731A0 (en) 2001-06-14
JP2001526241A (ja) 2001-12-18

Similar Documents

Publication Publication Date Title
Trinchieri et al. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation
CA2087525C (en) Adoptive immunotherapy with interleukin-7
AU693526B2 (en) Immuno-stimulatory monoclonal antibodies
JP7004761B2 (ja) 癌治療のための改善された細胞組成物および方法
US20040091476A1 (en) Methods of using human receptor protein 4-1BB
CA2313805A1 (en) Method for reducing susceptibility to hiv infection
Fujimiya et al. In vitro interleukin 12 activation of peripheral blood CD3 (+) CD56 (+) and CD3 (+) CD56 (-) gammadelta T cells from glioblastoma patients.
WO1995020605A9 (en) Immuno-stimulatory monoclonal antibodies
Kornbluth The emerging role of CD40 ligand in HIV infection
WO2018229163A1 (en) Methods of activating v delta 2 negative gamma delta t cells
Nagumo et al. Synergistic augmentative effect of interleukin‐10 and CD27/CD70 interactions on B‐cell immunoglobulin synthesis
Levitt et al. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
MXPA05007129A (es) Usos de la citocina de mamifero; reactivos relacionados.
US6074635A (en) T cell activation
Nguyen et al. Interleukin (IL)-15 enhances antibody-dependent cellular cytotoxicity and natural killer activity in neonatal cells
WO2003038062A2 (en) Generation of use of tc1 and tc2 cells
Bettens et al. Lymphokine gene expression related to CD4 T cell subset (CD45R/CDw29) phenotype conversion
Yamane et al. Effective stimulation for IL-12 p35 mRNA accumulation and bioactive IL-12 production of antigen-presenting cells interacted with Th cells
JP6963560B2 (ja) Ｔ細胞の拡張及び活性化の方法
US6319493B1 (en) Treatment of neoplastic disease with interleukin-10
Yoneda et al. Effects of tumour necrosis factor-alpha (TNF-α), IL-1β and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes
WO2000009150A2 (en) Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use
US6022536A (en) Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
EP0845994A1 (de) Kombinierte anwendung von interleukin-10 und cyclosporin für immunosuppressiontherapie
Zambello et al. IL‐12 is involved in the activation of CD3+ granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued